ArticleBMC cancer2026
Study protocol for hyperthermic intraperitoneal chemotherapy in the treatment of locally advanced gastric cancer after laparoscopic or robotic Gastrectomy with D2 lymphadenectomy: a phase III multicentre prospective randomized controlled clinical trial (HIPEC-09).
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05871099 (Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After Laparoscopic Gastrectomy With D2 Lymphadenectomy), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After Laparoscopic Gastrectomy With D2 Lymphadenectomy: A Phase III Multicenter Prospective Randomized Controlled Clinical Trial
Who cites it
1 citing paper in PubMed.
- Current Approaches and Emerging Strategies in the Treatment of Peritoneal Carcinomatosis.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundAlthough some prospective clinical studies have shown comparable oncological outcomes between laparoscopic and open surgery for advanced gastric cancer, the 3-year recurrence-free survival rate of patients who undergo laparoscopic radical gastrectomy is lower than that of patients who undergo open radical gastrectomy. Animal experiments have also shown that laparoscopic surgery may increase the risk of peritoneal metastasis during carbon dioxide pneumoperitoneum. Previous single-centre clinical trials have confirmed that HIPEC can effectively eliminate free cancer cells, thereby improving the survival rate of patients with advanced gastric cancer. In this study, we aimed to investigate the safety and efficacy of the combination of laparoscopic gastrectomy with HIPEC in advanced gastric cancer to reduce the incidence of peritoneal metastasis.
methodsA total of 616 patients will be randomly divided into 2 groups at a 1:1 ratio using central randomization after laparoscopic exploration in this prospective, randomized, controlled, open, multicentre clinical trial. The experimental arm will receive laparoscopic or robotic D2 surgery with 2 cycles of HIPEC treatment followed by 6–8 cycles of adjuvant chemotherapy, whereas the control group will undergo laparoscopic or robotic D2 surgery followed by 6–8 cycles of systemic chemotherapy. The primary endpoint for this study is 5-year recurrence-free survival. The secondary endpoints are the 5-year overall survival rate, peritoneal metastasis rate, peritoneal metastasis-free survival, regional recurrence rate, distant metastasis rate, toxicity and side effects of the treatment program. DISCUSSION: This is the first multicentre randomized controlled clinical study exploring whether HIPEC can prevent peritoneal metastasis after laparoscopic or robotic radical gastrectomy under carbon dioxide pneumoperitoneum for advanced gastric cancer. Minimally invasive surgery under carbon dioxide pneumoperitoneum can cause tremendous changes in the peritoneal microenvironment, increasing the risk of gastric cancer cell peritoneal dissemination and metastasis. In previous studies, the roles of HIPEC and laparoscopic gastrectomy for advanced gastric cancer have been confirmed. The innovation of this study lies in observing whether the combination of HIPEC can decrease the risk of peritoneal metastasis and recurrence in patients with advanced gastric cancer after laparoscopic or robotic gastrectomy under carbon dioxide pneumoperitoneum.
trial registrationThe trial was registered on 14/05/2023 under clinicaltrials.gov (Identifier: NCT05871099).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.